Results from a study using the database showed that patients with high expression of a certain gene signature had better outcomes with radiation therapy than without it.
Researchers are using GenomeDx's database to improve understanding of the genomic underpinnings of prostate cancer and advance personalized treatment strategies.
Launching the new biopsy-based version of Decipher, GenomeDx enters more direct competition with tests offered by Myriad Genetics and Genomic Health.
The firm will provide whole-genome profiling for Cedars-Sinai prostate cancer patients, who will also be tested with the Decipher Prostate Cancer Classifier.
The test is designed to predict prostate cancer aggressiveness and launched in the US in 2013.
The cloud-based Decipher GRID database will hold anonymized genomic data from the company's Decipher test and make it available to participating cancer centers.
The study shows that the genomic test may be able to differentiate between which patients would benefit from adjuvant radiation therapy or which do well with salvage treatment.
GenomeDx has implemented the software at its San Diego laboratory to track information related to the Decipher prostate test.
Palmetto will cover Decipher, an RNA expression-based assay test that predicts cancer aggressiveness using genomic biomarkers.
NEW YORK (GenomeWeb) – GenomeDx announced today an expansion of its research agreement with the Mayo Clinic to start a validation study for the expanded use of GenomeDx's Decipher Prostate Cancer Classifier.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.